Maravai LifeSciences Holdings, Inc. — Q1 2024 10-Q
Reporting period: Three months ended March 31, 2024; comparisons are with Q1 2023 unless stated otherwise. Maravai supplies life-science products through its Nucleic Acid Production and Biologics Safety Testing segments. Figures below are in U.S. dollars; financial statement amounts are in millions unless noted.
Financial performance
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | $64.2 | $79.0 |
| Gross profit / gross margin | $25.8 / 40.3% | $45.3 / 57.4% |
| Operating income (loss) | $(18.9) | $2.5 |
| Net income (loss) | $(22.7) | $(1.3) |
| Net loss attributable to Maravai / diluted loss per Class A share | $(12.1) / $(0.09) | $(0.1) / $0.00 |
| Adjusted EBITDA (non-GAAP) | $7.8 | $23.8 |
| Cash from operations | $(8.5) | $85.1 |
| Capital expenditures, net of government funding | $4.2 | $1.1 |
| Adjusted Free Cash Flow (non-GAAP) | $3.6 | $22.7 |
Revenue fell 18.8%. Nucleic Acid Production revenue decreased 25.1% to $46.0 million; Biologics Safety Testing revenue rose 3.4% to $18.2 million. The company reported total operating expenses of $83.0 million, including a $1.2 million restructuring benefit. Cost of revenue rose 13.8% despite lower sales, primarily due to lower manufacturing throughput and labor and overhead absorption. SG&A increased 5.7% to $40.9 million; R&D increased 21.4% to $5.0 million.
Balance sheet, debt and liquidity
- Cash and cash equivalents were $561.7 million at March 31, 2024, down from $575.0 million at year-end 2023. Current assets were $667.9 million and current liabilities $59.0 million.
- Term Loan principal was $531.8 million; reported long-term debt, net of unamortized costs, was $523.3 million. The loan rate was 8.31%, with maturity in October 2027. No revolving-credit borrowings were outstanding; the $180 million facility matures in October 2025. A $0.5 million letter of credit was outstanding.
- Finance lease liabilities totaled approximately $32.4 million. The company was in compliance with credit covenants and reported a first-lien net leverage ratio below 4.25:1.00.
- Operating cash flow was negative $8.5 million, versus positive $85.1 million a year earlier. Management attributed the current-period outflow in part to a $19.4 million reduction in accrued MyChem retention payments; the prior-year operating cash inflow benefited substantially from working-capital movements.
Changes, outlook and notable items
- Management linked weaker Nucleic Acid Production sales mainly to lower CleanCap analog demand from COVID-19 vaccine manufacturers and large GMP-services projects that did not recur. Management also cited lower early-stage biotech funding and spending, macroeconomic pressures, and contraction in Asia, particularly China, as potential continuing headwinds in 2024.
- The November 2023 cost realignment plan, including a workforce reduction of approximately 15%, was substantially completed in Q1 2024. The company said it expects no additional costs for the plan; remaining cash payments were expected by year-end 2024.
- Management projected 2024 capital expenditures of $30 million to $35 million, net of anticipated government funding, primarily for leasehold improvements and equipment at the Flanders San Diego Facility. No revenue or earnings guidance is provided in the supplied filing text.
- The company received $1.4 million of BARDA-related reimbursements in Q1, recorded as an offset to property and equipment. The agreement entails conditional government priority access and preferred pricing obligations during certain public-health emergencies.
- The Alphazyme acquisition includes contingent payments of up to $75 million tied to revenue targets, plus up to $9.3 million in retention-related payments subject to employment conditions; these amounts were not included in the contractual-obligations table. Contingent consideration recorded on the balance sheet was $2.0 million.
- The current Tax Receivable Agreement (TRA) liability was $7.1 million. The company had derecognized a $665.3 million non-current TRA liability at year-end 2023 because realization of the related tax benefits was not considered probable; future reassessment could result in recognition. The TRA generally entitles former owners to 85% of certain realized or deemed tax benefits.
- Revenue concentration remains relevant: Nacalai USA represented 14.8% of Q1 revenue and 24.5% of quarter-end net receivables. Maravai held approximately 52.7% of Topco LLC units; MLSH 1 held approximately 47.3%. GTCR-affiliated entities controlled approximately 56% of voting power.
Management stated that cash on hand, operating cash generation and continued access to credit facilities should be sufficient for cash requirements over the next 12 months and beyond. Key risks include customer spending and demand, customer and supplier concentration, product quality and regulatory requirements, competition, debt service and variable interest rates, and the uncertainty of future taxable income and TRA payments. A 100-basis-point interest-rate change was estimated to affect quarterly interest expense by approximately $1.3 million. No material changes to the 2023 Form 10-K risk factors were reported; disclosure controls were assessed as effective.
Important facts for investors to verify
- Whether nucleic-acid demand, CleanCap sales and manufacturing utilization recover, and whether the continued weakness described by management affects full-year results.
- Whether cash generation improves, given the Q1 operating cash outflow and the material year-over-year decline in Adjusted EBITDA; review the company’s non-GAAP definitions and reconciliations.
- Debt servicing capacity, variable-rate exposure, covenant terms and the 2027 term-loan maturity, alongside planned 2024 capital spending.
- Assumptions underlying the TRA liability and tax-benefit realizability, including the potential for future recognition of substantial non-current obligations.
- Alphazyme revenue milestones and employment conditions that could trigger contingent or retention payments, as well as BARDA funding conditions and obligations.
- Customer concentration and receivable exposure, particularly Nacalai USA, and the effects of macroeconomic and China-related demand pressures.